Video of The Value of MIPI and Ki-67 in Mantle Cell Lymphoma John P. Leonard, M.D., interim chair of the Department of Medicine, associate dean of clinical research, Richard T. Silver Distinguished Professor of Hematology... Read more
Patients with acute myeloid leukemia (AML) may have genetic mutations in their blood indicating they are at high risk of developing the disease about nine years before diagnosis , according to research from Weill Cornell... Read more
Video of Keynote Lecture: Silvia C. Formenti, MD, on Converting Tumors Into in Situ Vaccines With Radiation Therapy In her keynote lecture at the 2017 San Antonio Breast Cancer Symposium, Silvia C. Formenti, M.D., Professor... Read more
Dan A. Landau, M.D., Ph.D., assistant professor of m edicine in hematology/oncology and assistant professor in physiology and biophysics, will receive the 2017 Joanne Levy, M.D., Memorial Award for Outstanding Achievement... Read more
Dr. Jessica Tyler , who was recruited to Weill Cornell Medicine as a professor of pathology and laboratory medicine, has been elected a fellow of the American Association for the Advancement of Science (AAAS). Dr. Tyler was... Read more
Mark Souweidane, M.D., has been selected by the National Cancer Institute (NCI) to serve as a member of its Brain Malignancies Steering Committee (BMSC). The committee is charged with reviewing and prioritizing Phase 2 and... Read more
Would you trust a 3D-printed mini organ to test your drugs? The Daily Beast's article on the matter features the perspective of Todd Evans, Ph.D., Associate Dean for Research. Read more
Science journalist Sam Apple interviewed Dr. Lewis Cantley for his opinion piece in the Los Angeles Times on the connection between sugar and cancer. Read more
As you get older, your risk of developing cancer increases. That might seem obvious, but Ana Gomes, Ph.D., wants to know why. She’s studying a chemical, found more prominently in older people than young, and how it may be... Read more
Internationally renowned neuro-oncologist Dr. Howard A. Fine of Weill Cornell Medicine and NewYork-Presbyterian will receive a five-year, $6 million National Institutes of Health Director’s Pioneer Award for brain cancer... Read more
Two of the 2017 Prostate Cancer Foundation (PCF) Challenge Awards were awarded to teams including Meyer Cancer Center investigators. Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation ($1 million): Scott... Read more
American Society of Hematology (ASH) announced the names of five investigators whose research has been awarded $150,000 through the ASH Bridge Grant Program. Meyer Cancer Center member Selina Chen-Kiang, Ph.D. was one of the... Read more
Video of The Differences Between Right- and Left-Sided Tumors in Colon Cancer Manish A. Shah, M.D., discusses the differences between right- and left-sided colon cancer. Read more
This article by Tom Fleischman first appeared in the Cornell Chronicle . When breast cancer metastasizes, or spreads, one of its most likely destinations is bone. In fact, four in five metastatic breast cancer patients will... Read more
A phase II trial reported in the Journal of Clinical Oncolo gy by John P. Leonard, M.D., and collaborators showed no significant progression-free survival benefit of adding bortezomib to R-CHOP. Read more
This article by Bridget Kuehn first appeared in the Cornell Chronicle . Errors in the regulation of gene expression may contribute to the development of a common form of blood cancer and point to potential treatment... Read more
Dr. Olivier Elemento , a renowned computational biologist and leader in the field of computational genomics and biomedicine, has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill... Read more
John Babich, PhD, and collaborators have demonstrated a new way to identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. Read the featured basic article of the September... Read more
The Weill Cornell Medicine Specialized Programs of Research Excellence (SPORE) in Prostate Cancer, led by Mark Rubin, M.D., has been funded by the National Cancer Institute (NCI). Read more
